Compassionate Use of Omegaven IV Fat Emulsion

Status No longer available

Clinical Trial Summary

This protocol involves the compassionate use of intravenous fish oil infusion, Omegaven. The protocol involves infants and children with parenteral nutrition-associated liver disease to enable the reversal of elevated serum liver enzymes and direct bilirubin (cholestasis).

Clinical Trial Description

In the United States, patients dependent upon parenteral nutrition (PN) receive parenteral fat emulsions composed of soybean oils. Lipids are necessary in PN dependent patients due to their high caloric value and essential fatty acid content. Intravenous lipid emulsions have been implicated in predisposing patients to PN associated liver disease. Phytosterols such as those contained in soybean oils are thought to have a deleterious effect on biliary secretion. Accumulation of lipids in the hepatic Kupffer cells may further impair liver function.

Omega 6 fatty acid emulsions prevent fatty acid emulsions prevent fatty acid deficiency, it is thought that they are not cleared in a manner similar to enteral chylomicrons and therefore accumulate in the liver and resulting in steatotic liver injury (neonatal cholestasis). It is hypothesized that a fat emulsion comprised of omega 3 fatty acids (i.e.: fish oil), such as de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum. Animal studies have shown that IV fat emulsions such as fish oil that are high in eicosapentaenic and docosahexaenoic acid reduce impairment of bile flow which is seen in cholestasis caused by conventional fat emulsions. Furthermore, intravenous omega-e fatty acids are well tolerated and might reduce the hepatic dysfunction. By administering Omegaven in place of conventional phytosterol/soybean fat emulsion, the progression of PN-associated cholestasis can be prevented or reversed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02477345
Study type	Expanded Access
Source	Northwell Health
Contact
Status	No longer available
Phase	N/A

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02798861` - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed	`NCT01968395` - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure	Phase 4
Completed	`NCT01437969` - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting	`NCT00155376` - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography	Phase 4
Recruiting	`NCT00172705` - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique	N/A
Completed	`NCT04185454` - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese	N/A
Completed	`NCT02506335` - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease	Early Phase 1
Completed	`NCT02520609` - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed	`NCT02306018` - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation	N/A
Completed	`NCT01988753` - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed	`NCT01970904` - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients	N/A
Terminated	`NCT00741117` - Conjugated Hyperbilirubinemia and Pulse Oximetry	N/A
Enrolling by invitation	`NCT01483248` - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis	Phase 1/Phase 2
Completed	`NCT00074386` - Kidney and Liver Transplantation in People With HIV	N/A
Completed	`NCT00245830` - Ischemic Preconditioning of Liver in Cadaver Donors	N/A
Completed	`NCT02329821` - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection	N/A
Completed	`NCT01650181` - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis	Phase 4
Completed	`NCT01303549` - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients	Phase 4
Completed	`NCT00799851` - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices	Phase 4
Completed	`NCT00058890` - Gabapentin to Treat Itch in Patients With Liver Disease	Phase 3